Production of tissue engineered larynx and epithelium in a single gmp-compliant bioreactor

      Tissue engineered (TE) replacements offer a promising alternative for patients suffering from upper airway disorders for whom conventional treatment may not be suitable. In order to translate process development and preclinical work into viable clinical products it is necessary to adopt good manufacturing practice (GMP) processing.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect